By Katherine Hamilton
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
The Copenhagen, Denmark, biotechnology company said Monday Johnson & Johnson has decided it won't exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38, which is designed to treat people with certain blood cancers.
Genmab will not pursue further clinical development of the drug, it said, after evaluating the data, market landscape and its own portfolio prioritization.
Genmab had provided Johnson and Johsnon with data from a clinical proof-of-concept study for HexaBody-CD38 to treat multiple myeloma. Preliminary data demonstrated an overall response rate of 55%, while the rate of very good partial response or better was 29% and complete response or better was 7%.
Johnson & Johnson's decision does not impact Genmab's 2025 financial guidance, it said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 10, 2025 10:43 ET (14:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.